SBIR Phase I: Continuous Tissue Acquisition for Detection and Treatment of Barrett's Esophagus

SBIR 第一阶段：连续组织采集用于检测和治疗巴雷特食管

• 批准号: 1346136
• 负责人: Steven Golden
• 金额: $ 14.97万
• 依托单位: Barrostat Medical, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1346136&HistoricalAwards=false
• 关键词: SBIR; Phase; Continuous; Tissue; Acquisition

This Small Business Innovation Research (SBIR) Phase I project is directed to the development of a proprietary, tissue- harvesting technology for endoscopic biopsy of the esophagus in the setting of Barrett?s Esophagus (BE). Barrett?s is a result of chronic acid reflux (?heartburn? or GERD) and is a known precursor of adenocarcinoma of the esophagus. If patients with BE are monitored and treated appropriately the chance of the development of this devastating cancer can be minimized. Monitoring is done by serial biopsies at various time intervals. These intervals are determined by the presence and type of dysplastic tissue seen with an endoscope, which is diagnosed by collecting tissue samples. The method of using biopsy forceps through an endoscope as practiced currently has a detection rate of only 30% unless a rigorous protocol is followed, however this protocol is used infrequently because of the arduous nature of that protocol. The technology being developed will improve the standard of care by providing physicians with a device that achieves the detection rate (over 70%) of the recommended protocol with an efficient, easy to use alternative, without the expense of the new high tech visualization technologies under development.The broader impact/commercial potential of this project includes the improved patient care by enhancing the detection rate of patients with this pre-cancerous condition. When a patient progresses to having adenocarcinoma, the morbidity for that condition is very high and the treatment ? surgical and chemotherapies ? are very physical debilitating and costly. The incidence of adenocarcinoma of the esophagus is increased with the presence of obesity, which has become epidemic especially in the U.S. Esophageal carcinoma has become the fastest growing cancer but the incidence can be minimized by better screening and early treatment

这个小企业创新研究的第一阶段项目旨在开发一种专有的组织采集技术，用于Barrett？S食道(BE)的内窥镜活检。巴雷特？S是慢性胃酸反流(？烧心？或GERD)，是食管腺癌的已知先兆。如果BE患者得到适当的监测和治疗，这种毁灭性癌症的发展机会可以降到最低。监测是通过以不同的时间间隔进行连续活组织检查完成的。这些间隔由内窥镜看到的发育不良组织的存在和类型决定，内窥镜通过收集组织样本来诊断。目前实施的通过内窥镜使用活组织检查钳的方法，除非遵循严格的方案，否则检测率仅为30%，然而，由于该方案的艰巨性，该方案很少被使用。正在开发的技术将通过为医生提供一种达到推荐方案的检测率(超过70%)的设备来提高护理标准，该设备具有高效、易于使用的替代方案，而不需要花费正在开发的新的高科技可视化技术。该项目的更广泛的影响/商业潜力包括通过提高癌症前期疾病患者的检测率来改善患者护理。当患者进展为腺癌时，这种情况的发病率很高，治疗方法是什么？外科手术和化疗？都是非常耗费体力和费用的。食管腺癌的发病率随着肥胖的存在而增加，特别是在美国，食管腺癌已经成为增长最快的癌症，但通过更好的筛查和早期治疗可以将发病率降至最低